Fmr LLC Sells 14,709 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Fmr LLC decreased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,907,846 shares of the biotechnology company’s stock after selling 14,709 shares during the quarter. Fmr LLC owned about 0.08% of Ascendis Pharma A/S worth $732,790,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ASND. Avoro Capital Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after acquiring an additional 155,971 shares during the last quarter. Fred Alger Management LLC lifted its position in Ascendis Pharma A/S by 65.0% during the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after purchasing an additional 120,952 shares during the last quarter. Finally, Tri Locum Partners LP lifted its position in Ascendis Pharma A/S by 102.1% during the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock valued at $31,062,000 after purchasing an additional 115,092 shares during the last quarter.

Ascendis Pharma A/S Price Performance

ASND stock opened at $136.32 on Friday. The company has a market capitalization of $8.27 billion, a PE ratio of -16.87 and a beta of 0.66. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The firm’s 50-day moving average is $132.55 and its 200 day moving average is $132.21.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Sell-side analysts forecast that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. Citigroup increased their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.